Anaphylaxis following the use of a plasma-derived immunopurified Monoclate-P (R), and the recombinant Recombinate (R) and Kogenate (R) factor VIII: atherapeutic challenge

Authors
Pernod, G Armari, C Barro, C Plantaz, D Caperan, D Jacquot, C Polack, B
Citation
G. Pernod et al., Anaphylaxis following the use of a plasma-derived immunopurified Monoclate-P (R), and the recombinant Recombinate (R) and Kogenate (R) factor VIII: atherapeutic challenge, HAEMOPHILIA, 5(2), 1999, pp. 143-144
Citations number
7
Categorie Soggetti
Hematology
Journal title
HAEMOPHILIA
ISSN journal
13518216 → ACNP
Volume
5
Issue
2
Year of publication
1999
Pages
143 - 144
Database
ISI
SICI code
1351-8216(199903)5:2<143:AFTUOA>2.0.ZU;2-6
Abstract
We report the first case of an anaphylactic shock to three different FVIII concentrates, one immuopurified plasma-derived (Monoclate-P(R)) and two rec ombinant FVIII products (Recombinate(R) and Kogenate(R)). These shocks appe ared despite the use of antihistaminic drugs. The use of a highly purified plasma-derived FVIII allowed successful on-demand therapy without any antia llergic drug or desensitization.